
Friday, February 02, 2018 12:30:04 AM
Just checking in on the trials, and I see they also updated the trial info as of January 31, 2018
If I am not mistaken, the original required number of participants were 240, and now it reflects only a requirement of 200 participants. That is also great news for the company, and a huge positive when it comes to getting the trial done and FDA approval!
Observational [Patient Registry]
Estimated Enrollment : 200 participants
Observational Model: Other
Time Perspective: Other
Target Follow-Up Duration: 2 Years
Official Title: Collection of Safety, Efficacy and Resource Utilization Information in Patients Who Have Received Melphalan PHP With the Delcath Hepatic Delivery System for the Treatment of Unresectable Hepatic Malignancy
Actual Study Start Date : January 14, 2016
Estimated Primary Completion Date : January 2019
Estimated Study Completion Date : February 2019
Expect study completion by February 2019. With the relaxed enrollment criteria, and lower number of participants required. Who knows how close they are to reaching that 200th patient? also, this is not a blinded trial, so the company should know the 30-day results of those patients treated already. This and the fact that the Independent Safety Monitoring Committee recommended continuation without modifications tells me that things are going well! Had there been any adverse effects, the committee would have recommended discontinuing.
I am a believer of good things to come here, and that time is nearing!
IMHO
In My Own Personal Opinion Of Course!

Liked By
Spread the love. Be the first to like this post!
Recent DCTH News
- Delcath Systems to Participate at the BTIG MedTech, Digital Health, Life Sciences & Diagnostic Tools Conference on February 14 to 16 • PR Newswire (US) • 01/30/2023 01:30:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 01/23/2023 12:01:47 PM
- Notice of Effectiveness (effect) • Edgar (US Regulatory) • 01/23/2023 11:04:04 AM
- Delcath Systems Announces Updated Results from CHOPIN Phase 1b Trial Published in Cardiovascular and Interventional Radiology • PR Newswire (US) • 01/17/2023 01:00:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 01/10/2023 09:13:57 PM
- Securities Registration Statement (simplified Form) (s-3) • Edgar (US Regulatory) • 01/10/2023 09:08:24 PM
- Amended Statement of Ownership (sc 13g/a) • Edgar (US Regulatory) • 12/29/2022 10:28:09 PM
- Tender Offer Statement by Issuer (sc To-i) • Edgar (US Regulatory) • 12/21/2022 05:18:41 PM
- Amended Statement of Beneficial Ownership (sc 13d/a) • Edgar (US Regulatory) • 12/16/2022 10:07:45 PM
- Delcath Systems Announces Inducement of Grant Under NASDAQ Listing Rule 5635(C)(4) • PR Newswire (US) • 12/16/2022 09:15:00 PM
- Small Company Offering and Sale of Securities Without Registration (d) • Edgar (US Regulatory) • 12/16/2022 08:04:28 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 12/16/2022 02:32:48 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 12/14/2022 09:55:08 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 12/14/2022 09:43:16 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 12/14/2022 08:35:42 PM
- Delcath Systems Closes Private Placement of $6.2 Million • PR Newswire (US) • 12/13/2022 01:30:00 PM
- Delcath Systems Announces Private Placement of $6.2 Million • PR Newswire (US) • 12/08/2022 01:30:00 PM
- Results of a Single Center Study on Delcath's CHEMOSAT® Hepatic Delivery System In the Treatment of Cholangiocarcinoma Published in the Journal Clinical & Experimental Metastasis • PR Newswire (US) • 12/05/2022 02:00:00 PM
- Delcath Systems (DCTH) Receives a Buy from H.C. Wainwright • TipRanks • 11/10/2022 11:35:43 AM
- Analysts Offer Insights on Healthcare Companies: Delcath Systems (DCTH), Curis (CRIS) and AquaBounty Technologies (AQB) • TipRanks • 11/10/2022 11:21:12 AM
- Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 11/09/2022 09:15:00 PM
- Delcath Systems Reports Third Quarter 2022 Results and Provides Business Update • PR Newswire (US) • 11/08/2022 01:00:00 PM
- Delcath Systems to Host Third Quarter 2022 Results • PR Newswire (US) • 10/24/2022 08:05:00 PM
- Notice of Effectiveness (effect) • Edgar (US Regulatory) • 09/16/2022 10:02:39 AM
- Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) • Edgar (US Regulatory) • 09/15/2022 09:13:03 PM
FEATURED Goldshore Intersects 9.46 g/t Au over 7.45m in the Southwest Zone Widths of Mineralized System Expanded Significantly. • Feb 2, 2023 9:58 AM
FEATURED Hempacco and Snoop Dogg Create Joint Venture to Launch Consumer Goods Powerhouse of Hemp and Hemp-Derived Products • Feb 2, 2023 9:30 AM
FEATURED American Green (OTC:ERBB) Receives Equipment Lease Funding for its 40K s.f. Cypress Chill Cannabis Grow • Feb 2, 2023 7:03 AM
Trend Innovations Holding Inc. Thy News Application Review Year 2022 and Update Toward 2023 • TREN • Feb 2, 2023 2:00 PM
Kona Gold Beverage, Inc Announces Record Revenue Month in January Eclipsing Half a Million Dollars for the First Time • KGKG • Feb 2, 2023 9:00 AM
BioLife Sciences Inc. (OTC: BLFE) Announces Letter of Intent for Exclusive Licensing Deal with Canadian Firm • BLFE • Feb 2, 2023 8:32 AM